Practical management of patients with non–small-cell lung cancer treated with gefitinib
NT Shah, MG Kris, W Pao, LB Tyson… - Journal of Clinical …, 2005 - ascopubs.org
Purpose The use of gefitinib, the first drug approved to inhibit the epidermal growth factor
receptor tyrosine kinase, is indicated in patients with non–small-cell lung cancer with tumors …
receptor tyrosine kinase, is indicated in patients with non–small-cell lung cancer with tumors …
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib
H Asahina, S Oizumi, A Inoue, I Kinoshita, T Ishida… - Oncology, 2011 - karger.com
Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …
conducted the first prospective phase II study of gefitinib readministration in previous …
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non …
BACKGROUND: Only 15% of patients with non-small cell lung cancer (NSCLC) treated with
oral epidermal growth factor tyrosine kinase inhibitor gefitinib, as a second-line therapy have …
oral epidermal growth factor tyrosine kinase inhibitor gefitinib, as a second-line therapy have …
Gefitinib: an adverse effects profile
RJ Cersosimo - Expert opinion on drug safety, 2006 - Taylor & Francis
Gefitinib, an epidermal growth factor receptor inhibitor, is currently approved for use in
patients with advanced non-small cell lung cancer who have failed previous chemotherapy …
patients with advanced non-small cell lung cancer who have failed previous chemotherapy …
[HTML][HTML] Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
MK Mohamed, S Ramalingam, Y Lin, W Gooding… - Annals of oncology, 2005 - Elsevier
Abstract Background Gefitinib (Iressa®) is active as a single agent in the treatment of select
patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of …
patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of …
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial
MG Kris, RB Natale, RS Herbst, TJ Lynch Jr, D Prager… - Jama, 2003 - jamanetwork.com
ContextMore persons in the United States die from non–small cell lung cancer (NSCLC)
than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral …
than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral …
The role of gefitinib in lung cancer treatment
G Giaccone - Clinical cancer research, 2004 - AACR
Gefitinib (Iressa) is a novel targeted therapy that inhibits the tyrosine kinase activity of the
epidermal growth factor receptor by competitively blocking the ATP binding site. In …
epidermal growth factor receptor by competitively blocking the ATP binding site. In …
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
Dermatologic side effects associated with gefitinib therapy: clinical experience and management
RS Herbst, PM LoRusso, M Purdom, D Ward - Clinical lung cancer, 2003 - Elsevier
Abstract Gefitinib (ZD1839, Iressa™), a selective inhibitor of the epidermal growth factor
receptor—tyrosine kinase, is currently in clinical trials to treat a variety of solid tumors …
receptor—tyrosine kinase, is currently in clinical trials to treat a variety of solid tumors …
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status
GC Chang, KC Chen, TY Yang, MC Yin, CP Lin… - Investigational new …, 2005 - Springer
Advanced non-small-cell lung cancer (NSCLC) patients with poor performance status (PS)
are less likely to respond to chemotherapy, or to have an improvement in survival, but more …
are less likely to respond to chemotherapy, or to have an improvement in survival, but more …